Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) gapped down prior to trading on Monday. The stock had previously closed at $5.91, but opened at $5.53. Valneva shares last traded at $5.47, with a volume of 1,748 shares traded.

Analyst Ratings Changes

A number of research analysts have issued reports on VALN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research report on Monday, September 14th. TD Cowen began coverage on shares of Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Valneva currently has a consensus rating of “Reduce” and a consensus price target of $9.30.

Valneva Stock Up 3.3%

The business’s fifty day simple moving average is $6.36 and its 200 day simple moving average is $5.81. The company has a current ratio of 2.16, a quick ratio of 1.69 and a debt-to-equity ratio of 2.04. The stock has a market cap of $539.92 million, a price-to-earnings ratio of -2.70 and a beta of 1.53.

Valneva (NASDAQ:VALN) last issued its earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The business had revenue of $39.37 million for the quarter, compared to the consensus estimate of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. Equities analysts forecast that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.